Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by ReCode Therapeutics
< Previous
1
2
Next >
ReCode Therapeutics Achieves a First: Proof of Activity in Primary Ciliary Dyskinesia Patients
May 20, 2026
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Initiates Enrollment of Phase 2 Clinical Trial of RCT2100 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis
November 17, 2025
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update
September 29, 2025
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT2100 for the Treatment of Cystic Fibrosis
March 25, 2025
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Announces Additional Funding From the Cystic Fibrosis Foundation to Accelerate Development of Novel Gene Correction Therapeutics to Treat Cystic Fibrosis
November 18, 2024
From
ReCode Therapeutics
Via
Business Wire
ReCode Announces Two Key Additions to Scientific Advisory Board
October 01, 2024
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Presents Preclinical Data from its Cystic Fibrosis Program at the 2024 North American Cystic Fibrosis Conference (NACFC) in Boston
September 26, 2024
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Doses First Patient in Phase 1b Clinical Study of RCT2100 for the Treatment of Cystic Fibrosis
September 26, 2024
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Participate in Upcoming Investor Conferences
September 25, 2024
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT1100 for the Treatment of Primary Ciliary Dyskinesia
June 27, 2024
From
ReCode Therapeutics
Via
Business Wire
New Article Published in Science Highlights the Potential of ReCode Therapeutics’ Systemic Lung Delivery and CFTR Gene Correction
June 13, 2024
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Announces Appointment of Dean J. Mitchell as Chairman of Its Board of Directors
May 13, 2024
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Participate in May Conferences
May 01, 2024
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Study of Inhaled mRNA-Based Genetic Medicine, RCT2100, for the Treatment of Cystic Fibrosis
February 21, 2024
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Participate in February Conferences
February 20, 2024
From
ReCode Therapeutics
Via
Business Wire
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
February 15, 2024
From
ReCode Therapeutics
Via
Business Wire
Tickers
NTLA
ReCode Therapeutics Doses First Patient in Phase 1 Clinical Study of Novel mRNA-based Therapy for the Treatment of Primary Ciliary Dyskinesia
January 03, 2024
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Participate in November Conferences
November 10, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Announces Closing of Extension to Series B Financing
September 19, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Present at September Investor Conferences
September 07, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Appoints Erica Jefferson as Senior Vice President of Corporate Affairs
July 10, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Present at Jefferies Healthcare Conference
June 02, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D., as Senior Vice President, Clinical Development
April 17, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days
March 27, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Present at BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines
March 21, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Trial of Novel Disease-Modifying Genetic Medicine, RCT1100 for the Treatment of Primary Ciliary Dyskinesia
March 15, 2023
From
ReCode Therapeutics
Via
Business Wire
Recode Therapeutics Expands Leadership Team with Appointment of April Loui as Senior Vice President of Quality and CMC Regulatory Affairs
February 01, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Announces Strategic Investment from the Cystic Fibrosis Foundation to Accelerate Development of Novel mRNA Therapy
January 10, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Announces Strategic Collaboration with AskBio to Explore Single Vector Gene-Editing Platform
January 09, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
ReCode Therapeutics
Via
Business Wire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
